RPT2 Antibody

How to validate RPT2 antibody specificity in Western blotting for novel model organisms?

Methodological Framework:

• Perform parallel immunoblotting with:

  • Positive control: Cell lysate from RPT2-overexpressing systems (e.g., HEK293T transfected with pCMV-RPT2)

  • Negative control: RPT2 knockout lines (CRISPR/Cas9-generated) or siRNA-treated samples

  • Cross-reactivity panel: Lysates from phylogenetically related species (e.g., S. cerevisiae vs S. pombe)

Table 1: Validation data from source

Critical step: Pre-adsorb antibodies with recombinant RPT2 protein (10 μg/mL, 1 hr incubation) to confirm signal ablation .

What experimental controls are essential when distinguishing RPT2 isoforms in proteasome studies?

Three-Tier Control System:

• Genetic controls:

  • Use ΔRPT2 mutants complemented with isoform-specific rescue constructs (e.g., RPT2α vs RPT2β)

• Epitope mapping:

  • Validate antibody binding against isoform-unique regions (e.g., aa 120-135 in RPT2β vs aa 98-112 in RPT2α) through peptide array

• Functional assays:

  • Couple Western blotting with ATPase activity measurements (Km differences: 8.2 μM vs 14.7 μM between isoforms)

Data contradiction resolution: If isoform cross-reactivity exceeds 20%, employ tandem immunoprecipitation-MS using SILAC-labeled isoforms (ratio >5:1 considered specific) .

How to address RPT2 antibody cross-reactivity with homologous ATPase subunits?

Phylogenetic Exclusion Strategy:

• Generate sequence alignment of AAA+ ATPase family (Clustal Omega, BLOSUM62 matrix)

• Identify variable regions with <40% homology to RPT1/RPT3 (e.g., helical domain II)

• Validate using:

  • In vitro pull-down assays with recombinant homologs

  • Surface plasmon resonance (SPR) to measure binding kinetics (KD <10^-8 M acceptable)

Key finding: Rabbit polyclonals show 23% higher specificity than monoclonals for RPT2 C-terminal epitopes (n=12 studies) .

What protocol optimizes co-immunoprecipitation of RPT2-containing 19S proteasome complexes?

Native Co-IP Workflow:

• Lysis buffer: 25 mM HEPES, 150 mM NaCl, 2 mM Mg-ATP, 0.5% NP-40 (pH 7.4)

• Proteasome stabilization: Add 2 mM ATPγS and 0.01% digitonin during extraction

• Elution: Competing with 100 μM RPT2 peptide (aa 200-220) instead of harsh pH changes

Table 2: Co-IP efficiency across systems

Troubleshooting: If Rpn1 co-precipitation <60%, verify Mg²⁺ concentration (optimal 2-5 mM) .

How to quantify RPT2-dependent proteasome activity changes in disease models?

Triangulation Approach:

• Fluorogenic substrate assay:

  • Chymotrypsin-like: Suc-LLVY-AMC (λex/em=380/460)

  • Caspase-like: Z-LLE-AMC
    Include 10 μM MG132 as negative control

• Native PAGE activity profiling:

  • Resolve 26S/30S complexes (4% gel, 18 hr run)

  • Develop with 100 μM substrates + 0.02% SDS

• Single-molecule imaging:

  • TIRF microscopy with fluorophore-labeled 20S cores (30% increase in binding dwell time indicates RPT2 activation)

Critical validation: Correlate antibody signal intensity with proteolytic rates (R² >0.85 required) .

What multimodal imaging strategy captures RPT2 dynamics in living systems?

FLIM-FRET Protocol:

• Labeling:

  • RPT2-mTurquoise2 (donor)

  • 20S β5-subunit-sfGFP (acceptor)

• Acquisition:

  • 458 nm excitation, 480-520 nm donor channel

  • Lifetime decay analysis (τ <2.5 ns indicates interaction)

• Pharmacological perturbation:

  • 10 μM IU1 (proteasome inhibitor) increases FRET efficiency by 40%

Advanced tip: Combine with photoactivated localization microscopy (PALM) to map nanoscale proteasome clusters .

Resolving discordant RPT2 localization reports between IHC and biochemical fractionation

Root Cause Analysis Framework:

Case study: In A. thaliana roots, RPT2 antibodies detected 72 kDa bands (vs predicted 55 kDa) due to phosphorylation-mediated dimerization .

CRISPR-Cas9-mediated RPT2 tagging for endogenous antibody validation

Dual-Strategy Approach:

• Homology-directed repair:

  • Insert 3xFLAG tag before stop codon

  • Validate with anti-FLAG Western (1:2000) and RPT2 antibody (1:1000)

• Epitope swapping:

  • Replace native epitope (aa 50-65) with orthologous sequence

  • Test antibody cross-reactivity loss (≥90% reduction expected)

Key metric: Correlation between endogenous tag signal and antibody signal (R² >0.93 across N=5 cell lines) .

Implementing blinding protocols for RPT2 quantification in neurodegenerative studies

Quadruple-Blind Design:

• Sample coding by independent staff

• Automated image analysis (Ilastik/Fiji macros)

• Statistical unmasking only after QC approval

• Cross-validation with orthogonal methods (e.g., SRM-MS with heavy peptides)

*Data from **: Blinding reduces inter-lab variance from 38% to 12% in IHC quantification.

Accelerated degradation testing of RPT2 antibody lots

ICH Q1A Protocol:

Storage recommendation: Aliquot in PBS + 50% glycerol, store at -80°C with ≤3 freeze-thaw cycles .